Industry

Pharmaceuticals and Life Sciences

The pharmaceutical, biotech and life sciences sectors are key contributors to Canada’s economy, developing products and services that improve the quality of life for all Canadians.

The rapid development and adoption of virtual medicine is disrupting how people are cared for and how companies in the sector do business. The shift from treatment of disease to prevention, diagnostics and cure is attracting a host of exciting new entrants from both the traditional pharmaceutical, biotech and life sciences fields and from new players. As development occurs, the various industries in this ecosystem recognize the need to protect what they have created — the intellectual property rights of new inventions and processes.

Keeping pace with the fast-moving nature of these sectors also means managing the complex risks inherent in the existing commercial and regulatory environment.

How we can help

At Osler, our firm has been modelled to address client needs at every stage. Our top-ranked Intellectual Property team is respected for its diverse strengths, including excellence in IP litigation, particularly our leading patent litigation practice, and for securing intellectual property rights through prosecution, licensing, and strategic portfolio advice.

Osler acts as an essential business partner by developing and executing global intellectual property strategies in prosecution and litigation that align with our clients’ objectives. Our firm has a substantial presence in pharmaceutical-related litigation and dispute resolution, in particular patent and class action. Local and international clients from a broad range of industries retain Osler for our leading IP prosecution services before every level of the Canadian courts, as well as before international tribunals.

Our firm routinely acts as counsel to the world’s largest and leading generic pharmaceutical companies. Strategically situated in the major English and French-speaking R&D hubs of Toronto, Montréal, Vancouver and Ottawa, our lawyers help guide investors, emerging and established companies, and research organizations through all stages of growth.

Osler also represents many clients on the buy-side in this sector, including private equity groups, venture capital funds, angel investors and investment banks focused on this area of business. In addition to working with Canadian funds, our team advises various U.S. funds on their Canadian investing and exit transactions.

Our lawyers further bring expertise in corporate law, mergers and acquisitions, private and public financing transactions, fund formation, collaborations, technology transfer, licensing and regulatory matters. Our life sciences group members hold relevant degrees in experimental medicine, biochemistry, pharmacy, veterinary medicine, pharmacology and epidemiology.

Key Contacts

Nathalie Beauregard

Partner, Emerging and High Growth Companies, Montréal

Nathaniel Lipkus

Partner, Intellectual Property, Toronto

J. Bradley White

Partner, Intellectual Property, Ottawa


Representative Work


Latest Insights

  • Osler Update Oct 17, 2023

    It ended before it began: first private party sought leave to bring an ‘abuse of dominance’ application under the Competition Act

    Just two weeks after applying for leave to the Competition Tribunal seeking a remedial order under the Competition Act “abuse of dominance” provisions...

    Read more
  • Osler Update Feb 23, 2023

    Ontario proposes new legislation for private health facilities and surgical centres

    On February 21, 2023, the Ontario government tabled Bill 60, Your Health Act, 2023 (Bill 60), following its recent announcement of its plan to reduce ...

    Read more
    Ontario proposes new legislation for private health facilities and surgical centres
  • Osler Update Feb 23, 2023

    Implications of new proposed legislation on the credentialing and employment of healthcare workers in Ontario

    Healthcare organizations are well-advised to pay attention to the implications of Bill 60 on the credentialing and hiring (as applicable) of out-of-pr...

    Read more
  • Osler Update Nov 10, 2022

    PMPRB releases long-awaited draft guidelines regarding excessive drug pricing under new regime

    The Patented Medicine Prices Review Board (PMPRB) has updated its approach to excessive pricing. Osler’s Nathaniel Lipkus and Yael Mansour discuss the...

    Read more
    PMPRB releases long-awaited draft guidelines regarding excessive drug pricing under new regime
View all Insights
Stay up to date with our latest insights
Subscribe

Awards and Recognition

  • Chambers Canada: Canada’s Leading Lawyers for Business: Recognized in Life Sciences, Intellectual Property and IP Litigation
  • Who’s Who Legal: Osler lawyers recognized in Life Sciences

In the Media

  • Media Mentions Jun 17, 2024

    Health law lawyers advising clients on legal requirements arising from virtual care, AI, big data — Lexpert

    Like most sectors right now, healthcare is facing its own unique challenges when it comes to the adoption of artificial intelligence. In a Lexpert art...

    Read more
    Health law lawyers advising clients on legal requirements arising from virtual care, AI, big data — Lexpert
  • Osler News Apr 22, 2024

    Six Osler lawyers recognized by Who’s Who Legal Life Sciences — Canada

    Osler congratulations the six members of the firm who have earned the “Recommended” rating from Who’s Who Legal (WWL) Life Sciences — Canada.

    Read more
    Six Osler lawyers recognized by Who’s Who Legal Life Sciences — Canada
  • Media Mentions Oct 13, 2023

    Alberta’s Booming Tech Sector: The Making of Canada’s Silicon Valley – This Professional Life

    The growth and success of the tech sector in Alberta is helping drive the diversification of the economy.

    Read more
  • Media Mentions Jan 11, 2023

    Enforcing diagnostic method patents in a world of patchwork protection – Landslide

    Securing effective patent protection over inventive diagnostic methods continues to be a challenge in several jurisdictions, particularly in the U.S.

    Read more
View all